microdosingMicrodoseMicroStrong evidence

Two more controlled trials, two more null results

The most recent placebo-controlled microdosing work found nothing the placebo did not.

2026Published
Two randomised double-blind placebo-controlled trialsStudy type
Two trial cohortsSample
What our evidence ratings mean

What they did

Participants took repeated low doses of psilocybin truffles or placebo across two randomised double-blind trials in semi-naturalistic settings, with measures of cognitive control, memory, social cognition and wellbeing.

What they found

Microdosing did not significantly beat placebo on any behavioural or subjective measure once the results were corrected for multiple comparisons. Blinding held, and negative bodily sensations were more common in the active condition.

0 of 5outcome domains beat placebo

Worth knowing

Published online in October 2025 carrying a February 2026 issue date. This is the newest controlled evidence available and it points the same way as the two studies above it.

Prochazkova et al. Cognitive and subjective effects of psilocybin microdosing. Neuropharmacology, 2026.

Read the source

Keep reading

microdosingSelf-blinded microdosers improved, but so did the placebo groupmicrodosingWhen people guessed right, they felt moremicrodosingNearly nine thousand people, and microdosers reported lower anxiety and depression

This is the part of the research that maps most closely to what we make. It is also the thinnest evidence base on the shelf, which is why we describe our capsules as a ritual rather than a remedy. See the range.

Browse the library

Microdosing 8Depression 9Anxiety 6Addiction 9Cognition 6Ageing and injury 3Brain and plasticity 7Other conditions 9Safety 6All research 63

For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.